Regenerative Medicine Innovation Projects (RMIP) Investigator-Initiated Studies (Collaborative U01 Clinical Trial Not Allowed)
Agency: National Institutes of Health
Assistance Listings
- 93.837 -- Cardiovascular Diseases Research
- 93.121 -- Oral Diseases and Disorders Research
- 93.839 -- Blood Diseases and Resources Research
- 93.866 -- Aging Research
- 93.846 -- Arthritis, Musculoskeletal and Skin Diseases Research
- 93.350 -- National Center for Advancing Translational Sciences
- 93.847 -- Diabetes, Digestive, and Kidney Diseases Extramural Research
- 93.173 -- Research Related to Deafness and Communication Disorders
- 93.840 -- Translation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders
- 93.233 -- National Center on Sleep Disorders Research
- 93.867 -- Vision Research
- 93.855 -- Allergy and Infectious Diseases Research
- 93.853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders
- 93.286 -- Discovery and Applied Research for Technological Innovations to Improve Human Health
- 93.838 -- Lung Diseases Research
- 93.856 -- Microbiology and Infectious Diseases Research
- 93.242 -- Mental Health Research Grants
Archived opportunityLast Updated: May 13, 2026
View version history on Grants.gov
Description
The National Institutes of Health (NIH) participating Institutes and Centers, in coordination with the U.S. Food and Drug Administration, invite cooperative agreement (U01) applications to support investigator-initiated clinical research studies aimed at furthering the field of regenerative medicine (RM) using adult stem cells. These applications are expected to focus on innovative projects that propose solutions to widely recognized issues in the development of safe and effective RM therapies. Emphasis will be given to projects that address critical issues in product development relevant for regulatory...
submissions. Areas of focus may include improved tools, methods, standards, or applied science that support a better understanding and improved evaluation of in-depth product characterization, manufacturing, potency, identity, quality, safety, in vivo function and integration, or effectiveness. Toward these ends, the NIH will consider applications for late-stage preclinical research studies involving adult stem cells in the context of generating or supplementing the necessary evidence for clinical development, including, but not limited to, the submission of an Investigational New Drug (IND) or Investigational New Device Exemption (IDE) package; or to support such research conducted under an authorized IND or IDE.
Eligibility
Eligible applicants
Government
- County governments
- Federally recognized Native American tribal governments
- Public and Indian housing authorities
- State governments
- City or township governments
- Special district governments
Education
- Public and state institutions of higher education
- Independent school districts
- Private institutions of higher education
Nonprofit
- Other Native American tribal organizations
- Nonprofits non-higher education with 501(c)(3)
- Nonprofits non-higher education without 501(c)(3)
Business
- For-profit organizations other than small businesses
- Small businesses
Miscellaneous
- Other
Additional information
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
Grantor contact information
Description
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Documents
No documents are currently available.
Link to additional information
http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-18-030.html
Archived: November 24, 2018
Award
$--
Program Funding
--
Expected awards
$--
Award Minimum
$250,000
Award Maximum
Funding opportunity number:
RFA-HL-18-030
Cost sharing or matching requirement:
No
Funding instrument type:
Cooperative agreement
Opportunity Category:
Discretionary
Opportunity Category Explanation:
--
Category of Funding Activity:
Health
Food and nutrition
Category Explanation:
--
History
Version:
1
Posted date:
August 1, 2018
Archive date:
November 24, 2018
